论文部分内容阅读
2-1-1程序是于第0天在双臂三角肌接种2剂疫苗,第7和21天各接种1剂疫苗,第0天同时注射人狂犬病免疫球蛋白(HRIG)。研究对象为161名19～25岁的健康男性志愿者,接种疫苗前抗体均为阴性。其中107名接种者只接种狂犬病疫苗,使用的5种疫苗是人二倍体细胞狂犬病疫苗(HDCV),原代胎牛肾细胞(FBKC)疫苗、纯化的鸭胚疫苗(PDEV)、原代鸡胚细胞(PCEC)疫苗、Vero细胞疫苗(PVRV)。54名接种者接种疫苗和HRIG。根据5种不同疫苗,随机分为5个组。对所有接种者于第0、7、14、
The 2-1-1 procedure consisted of two doses of vaccine on deltoid muscle on day 0, one vaccine on days 7 and 21 and human rabies immunoglobulin (HRIG) on day 0. The subjects were 161 healthy male volunteers aged 19 to 25 years who had negative antibodies prior to vaccination. Of these 107 vaccinated rabies vaccines, only five vaccines were used: human diploid cell rabies vaccine (HDCV), primary fetal bovine kidney cell (FBKC) vaccine, purified duck embryo vaccine (PDEV), primary chicken Blastocyst (PCEC) vaccine, Vero cell vaccine (PVRV). 54 vaccinates vaccinated and HRIG. Five different vaccines were randomly divided into five groups. All vaccinations at 0, 7, 14,